Full Year Results 

Hikma signals US deal

Hikma signals US deal

Full-year figures for Hikma Pharmaceuticals (HIK) were warmly received amidst the general carnage in the market. Excluding exceptional items and other adjustments, core operating profit increased by 9 per cent at constant currencies to $508m (£391m), while net operating cash flow also rose a tenth to $472m.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now